Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorRabin Medical Center
About this trial
The goal of this clinical trial is to learn if a combination of Palbociclib and Sunitinib is safe and effective in various solid tumors.
The main questions it aims to answer are:
* Is the drugs combination safe for the participants? * Is the drug combination effective in all solid malignancies? It is a single arm study, phase 1b/2, dose escalation and expansion, to determine the safety, tolerability and initial efficacy of this combination.
Participants will:
* Take the drugs combination every day for 5 executive days, and 2 days of, in a 28 days cycle, for up to a year. * Visit the clinic once every 2 weeks for checkups and tests
Eligibility criteria
Qualifiers
Age ≥18 years
Patients who have failed all other appropriate lines of therapy or who have refused treatment(s) of choice
Life expectancy of greater than 8 weeks
Clinical performance status of ECOG 0-2
Disqualifiers
Age ≥18 years
Patients who have failed all other appropriate lines of therapy or who have refused treatment(s) of choice
Life expectancy of greater than 8 weeks
Clinical performance status of ECOG 0-2
Trial design
Treatments tested in this trial
- Palbociclib
- Sunitinib
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov